Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Botulinum Toxin Type A

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    228 result(s) found for: Botulinum Toxin Type A. Displaying page 5 of 12.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-006526-34 Sponsor Protocol Number: BTXA2008 Start Date*: 2008-12-19
    Sponsor Name:Gynækologisk-obstetrisk afd. G, Glostrup Hospital
    Full Title: Intravesikal instillation af Botulinum toxin type A til patienter med urge urininkontinens
    Medical condition: Urge urinary incontinence
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048335 Urinary incontinence aggravated LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021691-28 Sponsor Protocol Number: DAMS-7 Start Date*: 2011-11-04
    Sponsor Name:Hospital Vall d'Hebron
    Full Title: PILOT CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF BOTULINUM NEUROTOXIN TYPE- A IN SALIVARY GLANDS IN THE TREATMENT OF CHRONIC DROOLING IN PATIENTS WITH CEREBRAL PALSY: A CONTROLLED CLINIC...
    Medical condition: Hypersalivation (chronic sialorrhea)in patients with cerebral palsy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10039424 Salivary hypersecretion PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005197-78 Sponsor Protocol Number: 1 Start Date*: Information not available in EudraCT
    Sponsor Name:Queen's Medical Centre, Nottingham, University Hospital NHS Trust,
    Full Title: A multi-centre, randomised, parallel group, cross-over study comparing the efficacy and safety of double versus multiple injections of Botulinum Toxin type-A (Dysport®), into the gastrocnemius musc...
    Medical condition: Spasticity of the Gastrocnemius Muscle due to Cerebral Palsy
    Disease: Version SOC Term Classification Code Term Level
    8.0 10024132 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-017709-12 Sponsor Protocol Number: Y-55-52120-141 Start Date*: Information not available in EudraCT
    Sponsor Name:Ipsen Pharma SAS
    Full Title: A PHASE III, MULTICENTRE, DOUBLE BLIND, PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF DYSPORT USED IN THE TREATMENT OF LOWER LIMB SPASTICITY IN CHILDREN WIT...
    Medical condition: Lower limb spasticity in children with dynamic equinus foot deformity due to cerebral palsy.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10024132 Leg spasticity LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-001794-10 Sponsor Protocol Number: Y-97-52120-727 Start Date*: 2006-05-17
    Sponsor Name:Ipsen Ltd
    Full Title: A Phase IV, Randomised, Double-blind, Dose-ranging, Study in Children and Young People to determine the Optimal Dose of Botulinum Toxin Type-A (Dysport®) in Managing the Symptoms of Hip Muscle Spas...
    Medical condition: Chronic Hip Pain due to Cerebral Palsy
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001815-38 Sponsor Protocol Number: 191622-143 Start Date*: 2014-12-16
    Sponsor Name:Allergan Limited
    Full Title: Evaluation of the Safety and Efficacy of Treatment With BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Subjects With Facial Rhytides (Forehead Lines, Glabellar Lines, Lateral Canth...
    Medical condition: Facial Rhytides (Forehead Lines, Glabellar Lines, Lateral Canthal Lines)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10048043 Wrinkling LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002321-34 Sponsor Protocol Number: Y-52-52120-189 Start Date*: 2014-12-04
    Sponsor Name:Ipsen Innovation
    Full Title: A phase III, double blind, randomised, placebo controlled study to assess the efficacy and safety of a single treatment of Clostridium botulinum toxin type A to improve the appearance of moderate t...
    Medical condition: Moderate to severe Glabellar lines
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004530-16 Sponsor Protocol Number: 191622-090 Start Date*: 2008-02-27
    Sponsor Name:Allergan, Ltd.
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Single Treatment Cycle, Parallel Evaluation of the Safety, Efficacy and Immunogenicity of Two Formulations of BOTOX® (Botulinum Toxin Ty...
    Medical condition: Cervical dystonia: cervical dystonia that have never received treatment with botulinum toxin of any serotype for cervical dystonia or for any other indication
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) GB (Completed) PT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000259-35 Sponsor Protocol Number: 2020_03 Start Date*: 2022-04-29
    Sponsor Name:Centre Hospitalier Universitaire de Lille
    Full Title: Assessment of the interest of a peri-operative antibiotic strategy applied to patients with asymptomatic bacteriuria undergoing intra-vesical botulinum toxin A injections
    Medical condition: Overactive bladder (OAB) and/or detrusor overactivity (DO) in multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000161-32 Sponsor Protocol Number: CLIN-52120-452 Start Date*: 2021-08-11
    Sponsor Name:Ipsen Pharma
    Full Title: A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison with Onabotulinu...
    Medical condition: upper limb spasticity (ULS) of any aetiology (in US and France) or post-stroke ULS (in Canada)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-017412-32 Sponsor Protocol Number: NEURO1 Start Date*: 2011-12-13
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
    Full Title: RANDOMISED CONTROLLED TRIAL OF BOTULINUM TOXIN TYPE A AND B EFFICACY IN REDUCING DROOLING IN PARKINSON DISEASE
    Medical condition: Parkinson disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013363 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-009216-53 Sponsor Protocol Number: 191622-094 Start Date*: 2009-04-04
    Sponsor Name:Allergan Ltd
    Full Title: A Multicenter, Long-term Follow-up Study of the Safety and Efficacy of Two Dose Levels of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Urinary Incontinence Due to Ne...
    Medical condition: Urinary incontinence due to neurogenic detrusor overactivity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029279 Neurogenic bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) NL (Completed) GB (Completed) FR (Completed) DE (Completed) IT (Completed) ES (Completed) BE (Completed) AT (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2014-001860-36 Sponsor Protocol Number: 191622-142 Start Date*: 2014-12-19
    Sponsor Name:Allergan Limited
    Full Title: Evaluation of the Safety and Efficacy of Treatment With BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Subjects With Forehead and Glabellar Facial Rhytides
    Medical condition: Facial Rhytides (Forehead Lines, Glabellar Lines)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10048043 Wrinkling LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001979-16 Sponsor Protocol Number: M21-307 Start Date*: 2022-05-24
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) for the Prevention of Migraine in Subjects with Episodic Migraine
    Medical condition: Episodic Migraine
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004852 10082019 Episodic migraine LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Ongoing) SE (Prematurely Ended) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000554-38 Sponsor Protocol Number: D-FR-52120-221 Start Date*: 2015-07-24
    Sponsor Name:Ipsen Innovation
    Full Title: A Phase III, Multicenter, Double Blind, Randomised, Placebo Controlled Study to Assess the Efficacy and the Safety of a Single Cycle of Dysport Solution in the Treatment of Upper Limb Spasticity in...
    Medical condition: upper limb spastic hemiparesis due to stroke
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10058978 Spastic hemiparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004682-32 Sponsor Protocol Number: 2011-09 Start Date*: 2012-02-07
    Sponsor Name:FONDAZIONE ISTITUTO SAN RAFFAELE-G.GIGLIO
    Full Title: Intra-articular injection of botulinum toxin type A in hemiplegic shoulder pain: a multicentric, double blind randomised, versus steroid study.
    Medical condition: hemiplegic shoulder pain
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10028395 Musculoskeletal and connective tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004821-26 Sponsor Protocol Number: MRZ60201_3074_1 Start Date*: 2013-04-01
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: Prospective, double-blind, placebo-controlled, randomized, parallel-group, multi-center study with an open-label extension period to investigate the efficacy and safety of two different doses of NT...
    Medical condition: Bilateral Blepharospasm (BEB)
    Disease: Version SOC Term Classification Code Term Level
    15.1 10015919 - Eye disorders 10005159 Blepharospasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-021271-83 Sponsor Protocol Number: 191622-104 Start Date*: 2011-04-27
    Sponsor Name:Allergan Limited
    Full Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Extension Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Sub...
    Medical condition: Treatment of lateral canthal rhytides in the periorbital region (CFL)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10040954 Skin wrinkling LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023210-31 Sponsor Protocol Number: Y52-52120-155 Start Date*: 2012-02-24
    Sponsor Name:Ipsen Innovation
    Full Title: A PHASE IIA, MULTICENTRE, DOUBLE BLIND, SINGLE DOSE, PARALLEL GROUP, PLACEBO CONTROLLED, CLINICAL PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SINGLE DOSE, INTRA-DETRUSOR INJECTIONS OF 750 UNIT...
    Medical condition: NEUROGENIC DETRUSOR OVERACTIVITY
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004857 10012547 Detrusor hyperreflexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed) LT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-021401-20 Sponsor Protocol Number: MAF/AGN/Facial/011 Start Date*: 2010-10-20
    Sponsor Name:Allergan Pharmaceuticals Ireland
    Full Title: A Multicenter, Randomised, Double-Blind Study to Evaluate the Efficacy of VISTABEL® (20 units) in the Treatment of Glabellar Lines, When Compared to BOCOUTURE® (30 units)
    Medical condition: Moderate to severe glabellar lines, as assessed by Facial Wrinkle Scale with Photonumeric Guide (FWS) at full contraction
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 22:44:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA